WS #15252
Eli Lilly is facing jurisdictional challenges from the Seventh Circuit that threaten its plans to file retatrutide as a biologic, potentially shortening exclusivity and allowing generic competition. Meanwhile, Oracle's 20-year bond yields have spiked to 8.1%, reflecting market concerns over AI capex draining free cash flow. These developments highlight specific risks within the tech and healthcare sectors, contrasting with the broader macro bullishness and suggesting a stock-picking environment is critical.
Tech Regulatory & Competitive Risks
Eli Lilly is facing jurisdictional challenges from the Seventh Circuit that threaten its plans to file retatrutide as a biologic, potentially shortening exclusivity and allowing generic competition. Meanwhile, Oracle's 20-year bond yields have spiked to 8.1%, reflecting market concerns over AI capex draining free cash flow. These developments highlight specific risks within the tech and healthcare sectors, contrasting with the broader macro bullishness and suggesting a stock-picking environment is critical.